Comparing new immunotherapy to standard chemo for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug, Cadonilimab, against a chemo-immunotherapy combination for people with early-stage lung cancer that can be surgically removed. The goal is to see if the new drug works better before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that can be surgically removed, and it must be stage IB to IIIA.
- You cannot have received previous treatment for this cancer.
- You must be 18 or older and have a good performance status (able to do daily activities).
- You need to have at least one tumor that can be measured on scans.
- Your major organs (liver, kidneys, blood) must work well enough, and your lungs must handle surgery.
- You cannot have active autoimmune disease, uncontrolled infections, or unstable heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new immunotherapy drug (ivonescimab or penpulimab) to standard chemotherapy before surgery helps people with early-stage lung cancer. It's for people whose cancer can be surgically removed and who haven't had treatment yet.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
This study tests a new two-in-one immunotherapy (bispecific antibody) given before surgery to shrink advanced lung cancer. It compares this approach to a standard single-antibody treatment (Toripalimab) combined with chemotherapy, to see which works better.
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.